Regeneron Pharmaceuticals Inc (REGN) Q1 2026 Earnings Call Transcript

Why It Matters

The earnings mix underscores Regeneron's reliance on its biologic franchise to offset retinal market headwinds, while strong cash generation funds aggressive R&D and capacity expansion.

Key Takeaways

• EYLEA US sales plunge 39% amid Avastin competition
• Dupixent global sales rise 20%, driven by new indications
• Gross margin guidance lowered to 86‑87% after inventory write‑offs
• $7 billion manufacturing expansion announced across NY and NC
• Pipeline advances with four approvals and nine regulatory submissions

Pulse Analysis

Regeneron's first‑quarter results illustrate a classic biopharma dichotomy: a struggling retinal franchise contrasted with soaring biologics. The sharp 39% drop in U.S. EYLEA sales reflects a broader affordability squeeze, as gaps in co‑pay assistance push patients toward low‑cost off‑label Avastin. This shift not only erodes branded anti‑VEGF volumes but also reshapes market share dynamics, giving Avastin a six‑point gain. Analysts will watch how Regeneron’s proposed philanthropic matching program and potential pricing adjustments aim to restore patient access and stabilize the retinal segment.

Meanwhile, Dupixent and Libtayo continue to drive top‑line momentum. Dupixent’s 20% global sales increase, bolstered by recent approvals for chronic spontaneous urticaria and expanding COPD uptake, reinforces its position as a multi‑indication powerhouse in Type 2 inflammation. Libtayo’s 21% U.S. growth underscores its expanding role in both skin cancer and lung cancer markets. Upcoming regulatory milestones—including linvoseltamab for multiple myeloma, odronextamab for follicular lymphoma, and new Dupixent indications—promise to diversify revenue streams further and sustain growth beyond the current portfolio.

Financially, Regeneron’s $816 million free cash flow and a cash pile of $17.6 billion provide ample runway for strategic investments. The revised gross‑margin outlook, now 86‑87%, signals short‑term pressure from inventory write‑offs, yet the company’s aggressive $7 billion manufacturing expansion in New York and North Carolina positions it to meet future demand for both existing and pipeline products. Coupled with robust share repurchases and a steady dividend, the capital‑return strategy signals confidence to investors while funding the R&D engine that underpins Regeneron's long‑term growth narrative.